Karyopharm Therapeutics is asking that Xpovio (selinexor) be approved with Velcade (bortezomib) and low-dose dexamethasone to treat people with multiple myeloma after at least one line of therapy. The request was submitted to the U.S. Food and Drug Administration (FDA) in the form of a supplemental new drug application (sNDA). It is based on new data from the BOSTON Phase 3 trial (NCT03110562) recently presented at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific…
You must be logged in to read/download the full post.
The post Xpovio Triple Combo Before FDA for Previously Treated Myeloma Patients appeared first on BioNewsFeeds.